# 119-s-2561: Skin Substitute Access and Payment Reform Act of 2025

119-s-2561, Skin Substitute Access and Payment Reform Act of 2025, is a 119th Congress bill sponsored by Sen. Cassidy, Bill [R-LA] (R-LA); status introduced; PRIA reads it as touching household money (as of 2026-04-21).

- Canonical: https://policyrisk.com/legislation/119-s-2561
- As of: 2026-04-21
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Bill: 119-s-2561
- Congress: 119
- Title: Skin Substitute Access and Payment Reform Act of 2025
- Status: introduced
- Introduced: 2025-07-31
- Sponsor: Sen. Cassidy, Bill [R-LA] (R-LA)
- Cosponsors: 2
- Policy area: Health
- Touches household money: yes
- Last recorded action: 2026-04-21

## Summary

**Creates a unified Medicare payment and coverage framework for skin substitute products.** The bill would set a new single payment method, define which products count as skin substitutes, and require a consolidated billing code by January 1, 2026.

## Cosponsors (2)

- Sen. Hassan, Margaret Wood [D-NH] (D-NH), 2025-09-17T00:00:00.000Z
- Sen. Booker, Cory A. [D-NJ] (D-NJ), 2025-10-28T00:00:00.000Z

## Provisions PRIA read

- Medicare coverage and reporting rules: benefit, medium. If enacted, starting January 1, 2026 Medicare would evaluate skin substitute products under the usual 'reasonable and necessary' test. The Secretary could only find a product unsafe for contamination, serious infectious disease, or serious adverse reactions. The Secretary could not deny coverage so…
- One Medicare payment for skin substitutes: mixed, medium. If enacted, Medicare would pay one set amount for all skin substitute products starting January 1, 2026. The amount would be a volume-weighted average using fourth-quarter 2023 payment limits and units billed Oct 1–Dec 31, 2023. From 2027 onward the amount would be adjusted by the CPI‑U change thro…
- Define which skin products qualify: mixed, low. If enacted, the bill would define a 'skin substitute product' as a cellular, biological, or synthetic material applied to a wound and meant to stay in the wound bed. It would include products cleared or authorized under certain FDA or Public Health Service pathways. It would exclude items meant to…

## Related bills

- 119-s-5066: Health Equity and Accountability Act of 2026
- 119-s-4744: Take Care of America’s Veterans Act
- 119-s-1241: Sanctioning Russia Act of 2025
- 119-s-410: Love Lives On Act of 2025
- 119-s-1816: Improving Seniors’ Timely Access to Care Act of 2025
- 119-s-558: Antisemitism Awareness Act of 2025

## Sources
- [119-s-2561 on Congress.gov](https://www.congress.gov/bill/119th-congress/senate-bill/2561)

## Related
- [119-s-5066: Health Equity and Accountability Act of 2026](https://policyrisk.com/legislation/119-s-5066)
- [119-s-4744: Take Care of America’s Veterans Act](https://policyrisk.com/legislation/119-s-4744)
- [119-s-1241: Sanctioning Russia Act of 2025](https://policyrisk.com/legislation/119-s-1241)
- [119-s-410: Love Lives On Act of 2025](https://policyrisk.com/legislation/119-s-410)
- [119-s-1816: Improving Seniors’ Timely Access to Care Act of 2025](https://policyrisk.com/legislation/119-s-1816)
- [119-s-558: Antisemitism Awareness Act of 2025](https://policyrisk.com/legislation/119-s-558)
- [All bills in Congress](https://policyrisk.com/legislation)

Source: PRIA, https://policyrisk.com/legislation/119-s-2561 (as of 2026-04-21).